Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends

Ticker	Company	Market Cap	Dividend Yield	Payout Ratio	Last Dividend	Annual Dividend	Dividend Percentile	Dividend Dropped Count (L10Y)	Ex-dividend Date	Div. Payment Date
FONR	FONAR CORP	$112.91M	N/A	0.00%	N/A	N/A	N/A	N/A
IDXX	IDEXX LABORATORIES INC	$39.70B	N/A	0.00%	N/A	N/A	N/A	N/A
ICLR	ICON PLC	$24.07B	N/A	0.00%	N/A	N/A	N/A	N/A
STRR	STAR EQUITY HOLDINGS INC	$13.49M	N/A	0.00%	$0.5500	N/A	N/A	0
RVTY	REVVITY INC	$12.28B	0.35%	5.00%	$0.0700	$0.35	4%	0		2024-05-10
A	AGILENT TECHNOLOGIES INC	$38.81B	0.70%	21.60%	$0.2360	$0.92	11%	1		2024-04-24
MEDP	MEDPACE HOLDINGS INC	$11.51B	N/A	0.00%	N/A	N/A	N/A	N/A
NEOG	NEOGEN CORP	$2.58B	N/A	0.00%	N/A	N/A	N/A	N/A
TMO	THERMO FISHER SCIENTIFIC INC	$206.49B	0.27%	9.00%	$0.3900	$1.44	3%	0
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$11.68B	N/A	0.00%	N/A	N/A	N/A	N/A
QGEN	QIAGEN NV	$9.01B	3.24%	85.30%	$1.2800	$1.28	57%	0
SHC	SOTERA HEALTH CO	$3.08B	N/A	0.00%	N/A	N/A	N/A	N/A
ENZ	ENZO BIOCHEM INC	$57.89M	N/A	0.00%	N/A	N/A	N/A	N/A
LH	LABORATORY CORP OF AMERICA HOLDINGS	$16.77B	1.44%	60.00%	$0.7200	$2.88	28%	0	2024-05-28	2024-06-12
DHR	DANAHER CORP	$174.84B	0.44%	16.30%	$0.2700	$1.05	6%	2		2024-04-26
CSTL	CASTLE BIOSCIENCES INC	$527.04M	N/A	0.00%	N/A	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$1.64B	N/A	0.00%	N/A	N/A	N/A	N/A
DGX	QUEST DIAGNOSTICS INC	$13.94B	2.29%	37.40%	$0.7500	$2.88	43%	0		2024-04-22
MTD	METTLER TOLEDO INTERNATIONAL INC	$25.61B	N/A	0.00%	N/A	N/A	N/A	N/A
XGN	EXAGEN INC	$24.63M	N/A	0.00%	N/A	N/A	N/A	N/A
WAT	WATERS CORP	$17.42B	N/A	0.00%	N/A	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$87.24M	N/A	0.00%	N/A	N/A	N/A	N/A
SERA	SERA PROGNOSTICS INC	$317.45M	N/A	0.00%	N/A	N/A	N/A	N/A
IQV	IQVIA HOLDINGS INC	$41.23B	N/A	0.00%	N/A	N/A	N/A	N/A
PRPO	PRECIPIO INC	$9.59M	N/A	0.00%	N/A	N/A	N/A	N/A
PSNL	PERSONALIS INC	$61.11M	N/A	0.00%	N/A	N/A	N/A	N/A
EXAS	EXACT SCIENCES CORP	$11.52B	N/A	0.00%	N/A	N/A	N/A	N/A
NTRA	NATERA INC	$10.54B	N/A	0.00%	N/A	N/A	N/A	N/A
OLK	OLINK HOLDING AB (PUBL)	$2.77B	N/A	0.00%	N/A	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$33.86M	N/A	0.00%	N/A	N/A	N/A	N/A
FLGT	FULGENT GENETICS INC	$598.97M	N/A	0.00%	N/A	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$2.03B	N/A	0.00%	N/A	N/A	N/A	N/A
STIM	NEURONETICS INC	$113.97M	N/A	0.00%	N/A	N/A	N/A	N/A
DMTK	DERMTECH INC	$20.46M	N/A	0.00%	N/A	N/A	N/A	N/A
NEO	NEOGENOMICS INC	$1.76B	N/A	0.00%	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$81.92M	N/A	0.00%	N/A	N/A	N/A	N/A
OCX	ONCOCYTE CORP	$21.18M	N/A	0.00%	N/A	N/A	N/A	N/A
RDNT	RADNET INC	$3.26B	N/A	0.00%	N/A	N/A	N/A	N/A
BGLC	BIONEXUS GENE LAB CORP	$15.00M	N/A	0.00%	N/A	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$38.65M	N/A	0.00%	N/A	N/A	N/A	N/A
APDN	APPLIED DNA SCIENCES INC	$5.74M	N/A	0.00%	N/A	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$736.90M	N/A	0.00%	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$5.86M	N/A	0.00%	N/A	N/A	N/A	N/A
MDXH	MDXHEALTH SA	$6.20M	N/A	0.00%	N/A	N/A	N/A	N/A
CDNA	CAREDX INC	$417.85M	N/A	0.00%	N/A	N/A	N/A	N/A
BDSX	BIODESIX INC	$121.18M	N/A	0.00%	N/A	N/A	N/A	N/A
ME	23ANDME HOLDING CO	$243.87M	N/A	0.00%	N/A	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$2.57M	N/A	0.00%	N/A	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$13.22M	N/A	0.00%	N/A	N/A	N/A	N/A
ULS	UL SOLUTIONS INC	N/A	N/A	0.00%	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$98.17M	N/A	0.00%	$0.3000	N/A	N/A	0
NOTV	INOTIV INC	$121.22M	N/A	0.00%	N/A	N/A	N/A	N/A
AWH	ASPIRA WOMEN's HEALTH INC	$43.57M	N/A	0.00%	N/A	N/A	N/A	N/A
OPK	OPKO HEALTH INC	$857.30M	N/A	0.00%	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$50.64M	N/A	0.00%	N/A	N/A	N/A	N/A
GENE	GENETIC TECHNOLOGIES LTD	$563.24k	N/A	0.00%	N/A	N/A	N/A	N/A
MYGN	MYRIAD GENETICS INC	$1.66B	N/A	0.00%	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$3.83M	N/A	0.00%	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$32.13M	N/A	0.00%	N/A	N/A	N/A	N/A
ILMN	ILLUMINA INC	$18.54B	N/A	0.00%	N/A	N/A	N/A	N/A
PMD	PSYCHEMEDICS CORP	$14.70M	2.73%	-19.40%	$0.0700	$0.07	50%	1
MYNZ	MAINZ BIOMED NV	$19.13M	N/A	0.00%	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$14.41M	N/A	N/A	$1.1000	N/A	N/A	0
MMA	ALTA GLOBAL GROUP LTD	N/A	N/A	0.00%	N/A	N/A	N/A	N/A
CNTG	CENTOGENE NV	$12.72M	N/A	0.00%	N/A	N/A	N/A	N/A
TTOO	T2 BIOSYSTEMS INC	$16.48M	N/A	0.00%	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 7.65% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 37.06% over the past year, overperforming other diagnostic & research stocks by 47 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 18.71% from Icon's current stock price of $291.82.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -0.9% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 22.23% from Idexx Laboratories's current stock price of $477.79.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.24%, which is 2 percentage points higher than the diagnostic & research industry average of 1.43%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.29%, which is 1 percentage points higher than the diagnostic & research industry average of 1.43%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.44%, which is the same as the diagnostic & research industry average of 1.43%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.91% in the last day, and down -7.32% over the last week. Genetic Technologies was the among the top losers in the diagnostics & research industry, dropping -22.78% yesterday.

Genetic Technologies shares trading lower after the company announced a $2 million registered direct offering.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 6.38% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -53.69% in the past year. It has underperformed other stocks in the diagnostic & research industry by -44 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 7.65% in the past year. It has overperformed other stocks in the diagnostic & research industry by 17 percentage points.

Are diagnostic & research stocks a good buy now?

46.81% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 13.68% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.3x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.